An article in the June 16, 2004, issue of BioWorld Today should have said that in investigator-initiated studies, InterMune saw response rates in the 25 percent to 40 percent range for daily use of Infergen in combination with ribavirin in hepatitis C patients who had failed to respond to a previous course of therapy of pegylated interferon alga-2 plus ribavirin. Also, InterMune s Phase III trial is designed to evaluate once-daily use of Infergen in combination with ribavirin for those same type of patients for 48 weeks with six months of follow up.
To read more on related topics, click on one of the words below.